Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies. [PDF]
Diabetes CareMcCormick N +10 more
europepmc +1 more source
Cardioprotective glucose-lowering drugs, statins, and risk of first-time atherosclerotic cardiovascular disease in Denmark: a nationwide cohort study. [PDF]
Lancet Reg Health EurTernhamar T +3 more
europepmc +1 more source
Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis. [PDF]
Clin Mol HepatolChoi J +9 more
europepmc +1 more source
Correction to "Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial". [PDF]
Diabetes Obes Metabeuropepmc +1 more source
Related searches:
AbstractFor Abstract see ChemInform Abstract in Full Text.
Mark, Paetzel +3 more
openaire +2 more sources
Tripeptidyl-peptidase II: A multi-purpose peptidase
The International Journal of Biochemistry & Cell Biology, 2005Tripeptidyl-peptidase II is a high-molecular weight peptidase with a widespread distribution in eukaryotic cells. The enzyme sequentially removes tripeptides from a free N-terminus of longer peptides and also displays a low endopeptidase activity. A role for tripeptidyl-peptidase II in the formation of peptides for antigen presentation has recently ...
Birgitta, Tomkinson +1 more
openaire +2 more sources